Open AccessUveitis Therapy With Shark Variable Novel Antigen Receptor Domains Targeting Tumor Necrosis Factor Alpha or Inducible T-Cell Costimulatory Ligand
Author(s) -
Kathryn L. Pepple,
Leslie Wilson,
Russell N. Van Gelder,
Marina Kovaleva,
Obinna C. Ubah,
John Steven,
Caroline J. Barelle,
A.J. Porter
Publication year - 2019
Publication title -
translational vision science and technology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.508
H-Index - 21
ISSN - 2164-2591
DOI - 10.1167/tvst.8.5.11
Subject(s) - tumor necrosis factor alpha , cytokine , monocyte , medicine , immunology , chemokine , receptor , inflammation , uveitis , t cell , macrophage inflammatory protein , immune system
VNAR-Fc molecules are a next-generation therapeutic biologic that overcome the limitations of classical biologic monoclonal antibodies, such as complex structure, large size, and limited tissue penetration. This is a novel drug modality that could result in the development of new therapy options for patients with noninfectious uveitis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom